On October 21, 2022 Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, reported that its prospective data of 926 patients demonstrating the clinical utility of DCISionRT and its Residual Risk Subtype (RRt) was selected for a scientific session oral presentation at the 64th Annual American Society for Radiation Oncology (ASTRO) Meeting, to be held on October 23 – 26, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX (Press release, PreludeDx, OCT 21, 2022, View Source [SID1234622277]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to have our recent clinical utility and validation data on DCISionRT selected for oral presentation, at the prestigious ASTRO Annual Meeting," said Dan Forche, President and CEO of PreludeDx. "This new data is paradigm-changing and further enhances treatment decision making for radiation oncologists and their DCIS patients regarding personal radiation benefit."
Oral Presentation
Title: Number 176: Re-Thinking Clinicopathologic Risk Assessment in DCIS: Pooled Data from Validation Studies Comparing a 7-gene DCIS Assay to Clinicopathologic Features Alone
Presenter: Chirag S. Shah, MD, Director of Breast Radiation Oncology, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
Date: Monday, October 24, 5:40 PM CT
Additional PreludeDx ASTRO Poster Will Be Presented
Title: Number 2028: The PREDICT Registry Australia: A Prospective Registry to Evaluate the Clinical Utility of a Biomarker Assay on Treatment Decisions in Patients with DCIS Following Breast Conserving Surgery
Presenter: Yvonne Zissiadis Jr, MBBS, Radiation Oncologist, GenesisCare, Perth, Australia
Date: Monday, October 24, 3:00 PM CT
About DCISionRT for Breast DCIS
DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. DCISionRT, developed by PreludeDx on technology licensed from the University of California San Francisco, and built on research that began with funding from the National Cancer Institute, enables physicians to better understand the biology of DCIS. DCISionRT combines the latest innovations in molecular biology with risk-based assessment scores to assess a woman’s individual tumor biology along with other pathologic risk factors and provide a personalized recurrence risk. The test provides a Decision Score that identifies a woman’s risk as low or elevated. Unlike other risk assessment tools, the DCISionRT test combines protein expression from seven biomarkers and four clinicopathologic factors, using a non-linear algorithm to account for multiple interactions between individual factors in order to better interpret complex biological information. DCISionRT’s intelligent reporting provides a woman’s recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.